When to start and when to stop antifibrotic therapies
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive changes of the lung architecture causing cough and dyspnoea and ultimately leading to lung failure and death. Today, for the first time, two drugs that may reduce the inexorable progression of the disease are available, suggesting t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2017-10-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/26/145/170053.full |